Therapie des refraktären Asthmas mit Antikörpern

Zusammenfassung

In den aktuellen Asthma-Therapie-Empfehlungen der GINA (global initiative for asthma) wird in der Therapie-Stufe 5 der zusätzliche Einsatz von Biologika empfohlen. Die vorliegende Übersichtsarbeit beschreibt die Wirkungen und das klinische Einsatzgebiet der Antikörper gegen Immunglobulin E, IgE (Omalizumab), Interleukin-5, IL-5 (Mepolizumab, Reslizumab) oder den IL-5-Rezeptor (Benralizumab). Desweiteren wird ein Ausblick auf potentiell zukünftig in der klinischen Praxis einsetzbare Antikörper für die Therapie des refraktären Asthma (z. B. Dupilumab) gegeben.

Abstract

Current guidelines of the global initiative for asthma (GINA) recommend the addition of biologics in step 5 of the stepwise asthma treatment approach. This review gives an overview on the effects and the clinical role of antibodies targeting immunoglobulin E, IgE (Omalizumab), Interleukin-5, IL-5 (Mepolizumab, Reslizumab) or the IL-5 receptor (Benralizumab). In addition, potential future treatment options of refractory asthma with antibodies (for instance Dupilumab) are discussed.

Schlüsselwörter

Schweres Asthma - Antikörper - Immunglobulin E - Interleukin-5 - Eosinophile Granulozyten

Keywords

severa asthma - antibodies - immunoglobulin E - interleukin-5 - eosinophils

• Literatur

• 1 Lommatzsch M, Stoll P. Novel strategies for the treatment of asthma. Allergo J Int 2016; 25: 11-17
• 2 Lommatzsch M, Virchow JC. Severe asthma: definition, diagnosis and treatment. Dtsch Arztebl Int 2014; 111: 847-855
• 3 Lommatzsch M, Korn S, Buhl R, Virchow JC. Against all odds: anti-IgE for intrinsic asthma?. Thorax 2014; 69: 94-96
• 4 Teach SJ, Gill MA, Togias A et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 2015; 136: 1476-1485
• 5 Arm JP, Bottoli I, Skerjanec A et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (Ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 2014; 44: 1371-1385
• 6 Harris JM, Maciuca R, Bradley MS et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir Res 2016; 17: 29
• 7 Voskamp AL, Gillman A, Symons K et al. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract 2015; 3: 192-199
• 8 Maurer M, Rosen K, Hsieh HJ et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368: 924-935
• 9 Manga V, Humbert M, Djukanovic R et al. Blood Eosinophils and Serum IgE Predict Response to Omalizumab in Patients with Severe Allergic Asthma: INNOVATE Trial Post-Hoc Analysis. J Allergy Clin Immunol 2016; 137: AB16
• 10 Hanania NA, Wenzel S, Rosen K et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187: 804-811
• 11 Castro M, Zangrilli J, Wechsler ME et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3: 355-366
• 12 Castro M, Wenzel SE, Bleecker ER et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014; 2: 879-890
• 13 Bel EH, Wenzel SE, Thompson PJ et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371: 1189-1197
• 14 Ortega HG, Liu MC, Pavord ID et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: 1198-1207
• 15 Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659
• 16 Price DB, Rigazio A, Campbell JD et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 2015; 3: 849-858
• 17 Katz LE, Gleich GJ, Hartley BF et al. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc 2014; 11: 531-536
• 18 Wenzel S, Wang L, Pirozzi G et al. Dupilumab Improves Lung Function and Reduces Severe Exacerbations in Uncontrolled Asthmatics with Baseline Eosinophil Levels Above and Below 300 Cells / μL. Am J Respir Crit Care Med 2015; 191: A6362
• 19 Thaci D, Simpson EL, Beck LA et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016; 387: 40-52
• 20 Bachert C, Mannent L, Naclerio RM et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA 2016; 315: 469-479
• 21 Gauvreau GM, O’Byrne PM, Boulet LP et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014; 370: 2102-2010